Researchers develop Marburg virus treatment effective five days after infection
University of Texas Medical Branch at Galveston Apr 11, 2017
An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.
There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.
Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.
ÂIn this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus–infected non–human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus, said UTMBÂs Thomas Geisbert, professor in the department of microbiology and immunology. ÂThese findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.Â
The study was conducted in Biosafety Level (BSL)–4 at UTMBÂs Galveston National Laboratory. BSL–4 is a highly–restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL–4 laboratory located on an American university campus.
ÂThe level of protection observed by Dr. GeisbertÂs team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible, said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.
Go to Original
There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.
Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.
ÂIn this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus–infected non–human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus, said UTMBÂs Thomas Geisbert, professor in the department of microbiology and immunology. ÂThese findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.Â
The study was conducted in Biosafety Level (BSL)–4 at UTMBÂs Galveston National Laboratory. BSL–4 is a highly–restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL–4 laboratory located on an American university campus.
ÂThe level of protection observed by Dr. GeisbertÂs team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible, said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries